Feasibility, safety and efficacy of OsteoStrong® in postmenopausal women with low bone mineral density: A pilot study

IF 3.6 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Bone Pub Date : 2025-09-20 DOI:10.1016/j.bone.2025.117656

Jakub Mesinovic , Jack R. Ryan , Carrie-Anne Ng , Ayse Zengin , Peter R. Ebeling , David Scott

{"title":"Feasibility, safety and efficacy of OsteoStrong® in postmenopausal women with low bone mineral density: A pilot study","authors":"Jakub Mesinovic , Jack R. Ryan , Carrie-Anne Ng , Ayse Zengin , Peter R. Ebeling , David Scott","doi":"10.1016/j.bone.2025.117656","DOIUrl":null,"url":null,"abstract":"<div><div>OsteoStrong® is a brief, near-isometric loading exercise modality that targets bone health improvements by applying forces at relevant anatomical sites using specific equipment during ∼10-min, once weekly sessions. Evidence on adherence, safety and effectiveness is limited. In this single-arm pilot study, we determined the feasibility of 8 months of OsteoStrong® for postmenopausal women with low BMD, and measured changes in bone density, microarchitecture and strength, physical function and body composition. Forty-four postmenopausal women with low BMD (DXA-determined T-score < −1.0 but > − 3.0 at total hip and/or lumbar spine) attended supervised, once-weekly 10–15-min sessions at an OsteoStrong® clinic for 8 months. We calculated 8-month changes in areal BMD (aBMD), trabecular bone scores (TBS), HR-pQCT-determined volumetric BMD (vBMD) and bone microarchitecture and strength, as well as physical function and body composition. Thirty-eight women aged 61.2 ± 5.5 years completed the study. Two adverse events suspected to be intervention-related were recorded. Adherence was 83 ± 28 % overall and 93 ± 9 % in those who completed the study. At 8 months, there were no changes in total hip, femoral neck, and lumbar spine aBMD (all <em>P</em> > 0.05), while TBS decreased (<em>P</em> < 0.05). At the distal radius, total, trabecular and cortical vBMD and cortical thickness decreased (mean change: −0.007 mm [95 %CI: −0.012, −0.002]). At the distal tibia, cortical vBMD decreased and trabecular separation increased (mean change: 0.007 mm [95 %CI: 0.001, 0.012]). Chair stand time (mean change: −0.8 s [95 %CI: −1.2, −0.5]) and stair climb time (mean change: −0.1 s [95 %CI: −0.2, −0.002]) decreased, while SPPB scores increased (mean change: 0.2 [95 %CI: 0.03, 0.38]). There were no changes in other bone, physical function or body composition outcomes. These findings suggest that 8 months of OsteoStrong® does not significantly improve bone density, microarchitecture, or strength in healthy postmenopausal women with low BMD, despite good adherence and safety.</div><div>Australian New Zealand Clinical Trials Registration: ACTRN12620000224921p.</div></div>","PeriodicalId":9301,"journal":{"name":"Bone","volume":"201 ","pages":"Article 117656"},"PeriodicalIF":3.6000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S8756328225002686","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

OsteoStrong® is a brief, near-isometric loading exercise modality that targets bone health improvements by applying forces at relevant anatomical sites using specific equipment during ∼10-min, once weekly sessions. Evidence on adherence, safety and effectiveness is limited. In this single-arm pilot study, we determined the feasibility of 8 months of OsteoStrong® for postmenopausal women with low BMD, and measured changes in bone density, microarchitecture and strength, physical function and body composition. Forty-four postmenopausal women with low BMD (DXA-determined T-score < −1.0 but > − 3.0 at total hip and/or lumbar spine) attended supervised, once-weekly 10–15-min sessions at an OsteoStrong® clinic for 8 months. We calculated 8-month changes in areal BMD (aBMD), trabecular bone scores (TBS), HR-pQCT-determined volumetric BMD (vBMD) and bone microarchitecture and strength, as well as physical function and body composition. Thirty-eight women aged 61.2 ± 5.5 years completed the study. Two adverse events suspected to be intervention-related were recorded. Adherence was 83 ± 28 % overall and 93 ± 9 % in those who completed the study. At 8 months, there were no changes in total hip, femoral neck, and lumbar spine aBMD (all P > 0.05), while TBS decreased (P < 0.05). At the distal radius, total, trabecular and cortical vBMD and cortical thickness decreased (mean change: −0.007 mm [95 %CI: −0.012, −0.002]). At the distal tibia, cortical vBMD decreased and trabecular separation increased (mean change: 0.007 mm [95 %CI: 0.001, 0.012]). Chair stand time (mean change: −0.8 s [95 %CI: −1.2, −0.5]) and stair climb time (mean change: −0.1 s [95 %CI: −0.2, −0.002]) decreased, while SPPB scores increased (mean change: 0.2 [95 %CI: 0.03, 0.38]). There were no changes in other bone, physical function or body composition outcomes. These findings suggest that 8 months of OsteoStrong® does not significantly improve bone density, microarchitecture, or strength in healthy postmenopausal women with low BMD, despite good adherence and safety.

Australian New Zealand Clinical Trials Registration: ACTRN12620000224921p.

查看原文本刊更多论文

OsteoStrong®治疗绝经后低骨密度妇女的可行性、安全性和有效性：一项初步研究

OsteoStrong®是一种简短的、接近等距负荷的锻炼方式，通过使用特定设备在相关解剖部位施加力来改善骨骼健康，每次约10分钟，每周一次。关于依从性、安全性和有效性的证据有限。在这项单臂先导研究中，我们确定了8 个月的OsteoStrong®治疗绝经后低骨密度妇女的可行性，并测量了骨密度、微结构和强度、身体功能和身体成分的变化。44名骨密度低（dxa测定的全髋关节和/或腰椎t评分  - 3.0）的绝经后妇女在OsteoStrong®诊所接受监督，每周一次10-15分钟的治疗，为期8 个月。我们计算了8个月的面积骨密度（aBMD）、骨小梁评分（TBS）、hrpqct测定的体积骨密度（vBMD）、骨微结构和强度、身体功能和身体成分的变化。38名年龄为61.2 ± 5.5 岁的女性完成了研究。记录了两起疑似干预相关的不良事件。总体依从性为83 ± 28 %，完成研究的依从性为93 ± 9 %。8 个月时，全髋关节、股骨颈和腰椎aBMD无变化（P均为 > 0.05），而TBS下降（P均为0.05）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone 医学-内分泌学与代谢

CiteScore

8.90

自引率

4.90%

发文量

264

审稿时长

30 days

期刊介绍： BONE is an interdisciplinary forum for the rapid publication of original articles and reviews on basic, translational, and clinical aspects of bone and mineral metabolism. The Journal also encourages submissions related to interactions of bone with other organ systems, including cartilage, endocrine, muscle, fat, neural, vascular, gastrointestinal, hematopoietic, and immune systems. Particular attention is placed on the application of experimental studies to clinical practice.